Two new scientific published articles in the peer-reviewed magazine of the International Headache Society, confirm the basic mechanism of the Cefaly® device and detail its effect on the nervous system for the treatment of migraine.
The findings confirm remarkable central action on the brain by means of evoked cortical potential1. The rationale behind the specific neurostimulation parameters for generating the central action and its therapeutic effect have been published as well2 in a thorough review by doctor Stephen D. Silberstein. Previously published clinical trials about the mechanism of action demonstrated the major central action of the Cefaly® device on the nervous system through PET-Scan3 and functional MRI4.
“We are very pleased with the new published articles about the mechanisms of action of the Cefaly® device in the treatment of migraine. So far there are more than 14 published clinical trials demonstrating the safety and efficacy of the Cefaly® device not only for the acute treatment of migraine attacks but also for the prevention of migraine as well,” said Dr. Pierre Rigaux, the chief executive officer of CEFALY Technology. “The new articles and clinical trials are leading to important technological progress and the treatment is becoming more and more efficient. Cefaly® fulfills the unmet needs of patients who are not satisfied, or cannot be treated, or do not tolerate migraine medications. It is through these technological improvements that Cefaly® will become the first-line treatment with the best safety/efficacy ratio for migraineurs, while remaining the cheapest overall treatment.”
The Cefaly® Dual medical device was recently cleared by the FDA for its two settings: one for the acute treatment of migraine attacks and the other for migraine prophylaxis.
Migraine is the leading cause of disability among neurological disorders in the United States according to the American Migraine Foundation5. An estimated 39 million Americans suffer from migraine. Migraine can be extremely disabling and costly, accounting for more than an estimated $36 billion in direct (e.g. doctor visits, medications) and indirect (e.g. missed work, lost productivity) expenses each year in the United States.
About CEFALY Technology
CEFALY Technology is a Belgium-based company, with US offices based in Wilton, Connecticut, specializing in electronics for medical applications. It has developed external cranial stimulation technology for applications in the field of neurology; in particular for treating migraines. For more information, visit http://www.cefaly.us. Find Cefaly® on Twitter: @Cefaly and on Facebook: http://www.facebook.com/CefalyEN.
1 Effects of external trigeminal nerve stimulation (eTNS) on laser evoked cortical potentials (LEP): A pilot study in migraine patients and controls. 2018 Jun;38(7):1245-1256
U.S. National Library of Medicine. https://www.ncbi.nlm.nih.gov/pubmed/28856913
2 Rationale for electrical parameter determination in external trigeminal nerve stimulation (eTNS) for migraine. Cephalalgia. 2018 Aug 23:333102418796781
U.S. National Library of Medicine. https://www.ncbi.nlm.nih.gov/pubmed/30139273
3 Cerebral metabolism before and after external trigeminal nerve stimulation in episodic migraine. 2017 Aug;37(9):881-891
U.S. National Library of Medicine. https://www.ncbi.nlm.nih.gov/pubmed/27342225
4 Functional Changes of the Perigenual Part of the Anterior Cingulate Cortex after External Trigeminal Neurostimulation in Migraine Patients. Front Neurol. 2017 Jun 15;8:282
U.S. National Library of Medicine. https://www.ncbi.nlm.nih.gov/pubmed/28663737
5 Migraine facts. Migraine Research Foundation website. http://migraineresearchfoundation.org/about-migraine/migraine-facts/. Accessed September 26, 2018.